Company intelligence / Profile preview
Zymeworks Inc.
Middletown, Delaware, United Stateszymeworks.com ↗
- Ownership
- Public · ZYME
- Employees
- ~278
- Development stage
- Commercial
01
Overview
Zymeworks’ lead asset zanidatamab (Ziihera®, zanidatamab-hrii) received FDA approval for previously-treated unresectable/metastatic HER2-positive BTC. Zanidatamab continues to be evaluated in multiple global clinical trials across several HER2-expressing cancers. Additional assets such as ZW191 and ZW171 are in early clinical development targeting solid tumors with novel mechanisms of action. The company’s pipeline leverages its proprietary platforms to address significant unmet needs in oncology and immune-mediated diseases
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody-drug conjugates (ADCs)bispecific antibodiesmultispecific antibody therapeuticsprotein therapeutics
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Jazz Pharmaceuticals – exclusive rights to develop/commercialize zanidatamab in key markets including US/EU/JapanBeiGene – exclusive rights to develop/commercialize zanidatamab in certain Asian territories including ChinaGSK – licensing/collaboration agreement on bispecific/multifunctional antibody technology/platforms
04
Financials
- Market cap
- $2.1B
- Total revenue
- $106M
- Enterprise value
- $2.1B
Beyond the preview
Go deeper on Zymeworks Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zymeworks Inc..